Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021
Matthew E. Oster(Centers for Disease Control and Prevention), Tom T. Shimabukuro(Centers for Disease Control and Prevention)
Cited by 670
Related Papers
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602
Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study
|The Lancet Child & Adolescent Health|2022|78
Databases for Congenital Heart Defect Public Health Studies Across the Lifespan
|Journal of the American Heart Association|2016|33